

**SWOG
PUBLICATIONS LIST
CANCER CARE DELIVERY COMMITTEE**
(previously Outcomes & Comparative Effectiveness Committee)
2017

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
CANCER CARE DELIVERY COMMITTEE Published/Accepted (2017)			
S1415CD	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: The TrACER study. A Bansal, SD Sullivan, DL Hershman, GH. Lyman, WE Barlow, JS McCune , SD Ramsey. <u>Journal of Comparative Effectiveness Research</u> , 2017 Jul;6(5):461-470. Epub 2017 Jul 7. PMID28686055 https://www.ncbi.nlm.nih.gov/pubmed/28686055		
None	Characterizing 18 years of death with dignity in Oregon. C Blanke, M LeBlanc, D Hershman, L Ellis, F Meyskens. <u>JAMA Oncology</u> 2017 Apr 6 [Epub ahead of print]. PMID28384683 https://www.ncbi.nlm.nih.gov/pubmed/28384683	n/a	n/a
None	Words matter: restoring respect and dignity when referring to people with cancer. LM Ellis, CD Blanke, E Kohn. <u>Cancer</u> Jul 1;123(13):2390-2391, 2017. Feb 9. [Epub ahead of print]. Commentary. PMID28182266 https://www.ncbi.nlm.nih.gov/pubmed/28182266	n/a	n/a
None	Feasibility of a centralized clinical trials coverage analysis: a joint initiative of the American Society for Clinical Oncology (ASCO) and the National Cancer Institute (NCI). C Szczepanek, P Hurley, M Good, A Denicoff, K Willenberg, C Dawson, D Kurbegov. <u>Journal Of Oncology Practice</u> , Jun;13(6):395-400, 2017. May 8: [Epub ahead of print]. PMID28481681 https://www.ncbi.nlm.nih.gov/pubmed/28481681	n/a	n/a
None	Responding to patient requests for hastened death: physician aid in dying and the clinical oncologist. CD Blanke. <u>Journal of Oncology Practice</u> , in press.		
Multiple*	The effect of positive SWOG treatment trials on survival of patients with cancer in the US population. JM Unger, M LeBlanc, CD Blanke. <u>JAMA Oncology</u> , 2017 Jun 5. doi: 10.1001/jamaoncol.2017.0762. [Epub ahead of print].*studies: SWG01, SWG02, S7436, S7704, S7817, S8494, S8501, S8591, S8624, S8710, S8736,S8797, S8814, S8892, S8897, S8949, S9008, S9126,S9210, S9308, S9916, S0226, S0777. PMID28586789 https://www.ncbi.nlm.nih.gov/pubmed/28586789		

CANCER CARE DELIVERY COMMITTEE Manuscripts Submitted (2017)

S0000_S9217	The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials. JM Unger, WE Barlow, CM Tangen, SD Ramsey, IM Thompson, Jr., EA Klein, M LeBlanc, CD Blanke, PJ Goodman, LM Minasian, DL Hershman. <u>JCO Clinical Cancer Informatics, under review.</u>	n/a	n/a
S9217	Long term risk of prostate cancer on the Prostate Cancer Prevention Trial (SWOG S9217). JM Unger, DL Hershman, C Till, CM Tangen, WE Barlow, SD Ramsey, PJ Goodman, IM Thompson, Jr. <u>JAMA Oncology, under review.</u>		
Multiple*	Survival by Hispanic ethnicity among SWOG cancer clinical trials patients. M Chavez-MacGregor, JM Unger, A Moseley, S Ramsey, DL Hershman, <u>Cancer Epidemiology Biomarkers and Prevention, under review.</u> [*studies: S8516, S8600, S8809, S8814, S8894, S8897, S8905, S9008, S9031, S9125, S9210, S9240, S9304, S9308, S9313, S9321, S9333, S9346, S9349, S9415, S9420, S9509, S9623, S9704, S9800, S9911, S9916, S0003, S0012, S0016, S0033, S0106, S0221, S0226, S0232, S0307, S0421, S0500] .	n/a	n/a

CANCER CARE DELIVERY COMMITTEE Abstracts Published/Presented/Accepted (2017)

S0000_S9217	The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials. J Unger, W Barlow, C Tangen, S Ramsey, I Thompson Jr., E Klein, M LeBlanc, C Blanke, P Goodman, L Minasian, DL Hershman. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session; J Clin Oncol 35, 2017 (suppl; abstr 1541). http://abstracts.asco.org/199/AbstView_199_181935.html		
S1415CD	Consistency of standing orders for primary prophylactic CSF within a National Network of Community Oncology Practices: SWOG Intergroup Trial S1415CD. S Ramsey, D Hershman, A Bell-Brown, K Watabayashi, K Kreizenbeck, S Sullivan, A Bansal, W Barlow, K Arnold, GH Lyman. American Association for Cancer Research (April 1-5, 2017, Washington, DC), poster, abstr. 2767/ 7. http://www.abstractsonline.com/pp8/#!/4292/presentation/2013		
Multiple	Impact of value of information analyses on SWOG's clinical trial capsule scoring. JJ Carlson, D Kim, G Guzauskas, C Bennette, D Hershman, L Baker, N Hendrix, A Basu, DL Veenstra, SD Ramsey. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), publication only; J Clin Oncol 35, 2017 (suppl; abstr e18311). http://abstracts.asco.org/199/AbstView_199_191486.html		
Multiple*	Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials. A Barzi, D Hershman, C Till, H-J Lenz, J Unger. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session; J Clin Oncol 35, 2017 (suppl; abstr 10056). http://abstracts.asco.org/199/AbstView_199_184332.html [*S9304, S9415, and S9420]; (see also GI)		

Multiple	<p>The impact of positive SWOG treatment trials on population survival. JM Unger, M LeBlanc, CD Blanke. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion; J Clin Oncol 35, 2017 (suppl; abstr 6513). http://abstracts.asco.org/199/AbstView_199_182040.html [*studies: SWG01, SWG02, S7436, S7704, S7817, S8494, S8501, S8591, S8624, S8710, S8736, S8797, S8814, S8892, S8897, S8949, S9008, S9126, S9210, S9308, S9916, S0226, S0777]</p>		
Multiple	<p>National coverage analyses for NCI clinical trials: A pilot project to reduce participation barriers. A Denicoff, G Mishkin, MJ Good, L Patrichuk, L Ragard, KR Hurtado, K Willenberg, CM Szczepanek, C Dawson, M Alexander-Young, DL Strandberg, J Kardell, S McCartney, MB Sullivan, M Kelly, M Montello, WJ McCaskill-Stevens, JS Abrams, MM Mooney. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session. J Clin Oncol 35, 2017 (suppl; abstr 6542). http://abstracts.asco.org/199/AbstView_199_188423.html</p>		
None	<p>Increasing the availability of statistical tools through mobile development. C Cook, T Phillips, M LeBlanc. Society for Clinical Trials Annual Meeting (May 7-10, 2017, Liverpool, UK), poster.</p>	n/a	n/a

**SWOG
PUBLICATIONS LIST
CANCER CARE DELIVERY COMMITTEE**
(previously Outcomes & Comparative Effectiveness Committee)
2016

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
CANCER CARE DELIVERY COMMITTEE Published/Accepted (2016)			
S0316	Patient income level and cancer clinical trial participation in a prospective survey study. [Research Letter] JM Unger, JR Gralow, KS Albain, SD Ramsey, DL Hershman. <u>JAMA Oncology</u> , Jan 1;2(1):137-139, 2016. PMID26468994; PMC4824189 http://www.ncbi.nlm.nih.gov/pubmed/26468994	8/1/04	6/15/08
S1204	Stepwise development of a cancer care delivery research study to evaluate viral infections in cancer patients: SWOG S1204. JM Unger, DL Hershman, K Arnold, R Loomba, R Chugh, JP Hwang, MA O'Rourke, N Bhadkamkar, LX Wang, AB Siegel, TP Cooley, JL Berenberg, BB Bridges, SD Ramsey. <u>Future Oncology</u> , May;12(10):1219-1231, 2016; 2016 Mar 8. [Epub ahead of print]. PMID26952901; PMC4864045 http://www.ncbi.nlm.nih.gov/pubmed/26952901	n/a	n/a
S9217	Long-term consequences of intervention following receipt of finasteride or placebo in the Prostate Cancer Prevention Trial (SWOG S9217). J Unger, C Till, I Thompson, C Tangen, P Goodman, J Wright, W Barlow, S Ramsey, L Minasian, D Hershman. <u>Journal of the National Cancer Institute</u> , Aug 26;108(12). pii: djw168. doi: 10.1093/jnci/djw168. Print 2016 Dec. PMID27565902 http://www.ncbi.nlm.nih.gov/pubmed/27565902	2/1/00	11/1/06
S9346	Adverse health events following intermittent and continuous androgen deprivation in metastatic prostate cancer patients. DL Hershman, JM Unger, JD Wright, S Ramsey, C Till, CM Tangen, W Barlow, C Blanke, IM Thompson, M Hussain. <u>JAMA Oncology</u> , Apr;2(4):453-461, 2016. 2015 Dec 23:1-9. doi: 10.1001/jamaoncol.2015.4655. [Epub ahead of print]. PMID26720308; PMC4852142 http://www.ncbi.nlm.nih.gov/pubmed/26720308	n/a	n/a
S9346	Adverse health effects of intermittent vs continuous androgen deprivation therapy for metastatic prostate cancer - Reply. DL Hershman, JM Unger. <u>JAMA Oncology</u> 2016 May 1;2(5):686-687. PMID27244679 https://www.ncbi.nlm.nih.gov/pubmed/27244679	n/a	n/a
S9916	Identifying severe adverse event clusters using the National Cancer Institute's Common Terminology Criteria for Adverse Events. X Zhong, EA Lim, DL Hershman, CM Moinpour, J Unger, SM Lee. <u>Journal of Oncology Practice</u> , Mar;12(3):245-246, 2016. PMID26907453; PMC Journal – In Process. http://www.ncbi.nlm.nih.gov/pubmed/26907453	10/15/99	1/15/03

Multiple	The scientific impact of positive and negative phase III cancer clinical trials. JM Unger, WE Barlow, SD Ramsey, M LeBlanc, CD Blanke, DL Hershman. <u>JAMA Oncology</u> , Jul 1;2(7):875-881, 2016. 2016 Mar 10 [Epub ahead of print]. PMID: 26967260 http://www.ncbi.nlm.nih.gov/pubmed/26967260		
Multiple	Measuring the real clinical impact of randomized clinical trials in oncology-reply: beyond citation counts. JM Unger, WE Barlow, DL Hershman. <u>JAMA Oncology</u> Nov 1;2(11):1511, 2016. 2016 Jun 23 [Epub ahead of print]. PMID: 27355398; PMC n/a – correspondence. http://www.ncbi.nlm.nih.gov/pubmed/27355398		
Multiple	The role of clinical trial participation in cancer research: barriers, evidence, and strategies. JM Unger, E Cook, E Tai, A Bleyer. <u>American Society of Clinical Oncology Educational Book</u> 35:185-198, 2016. PMID27249699 http://www.ncbi.nlm.nih.gov/pubmed/27249699		
Multiple	Predicting low accrual in the National Cancer Institute's Cooperative Group Clinical Trials. CS Bennette, SD Ramsey, CL McDermott, JJ Carlson, A Basu, DL Veenstra. <u>Journal of the National Cancer Institute</u> , 2015 Dec 29;108(2). pii: djv324. doi: 10.1093/jnci/djv324. Print 2016 Feb. PMID26714555; PMC Journal – In Process http://www.ncbi.nlm.nih.gov/pubmed/26714555	n/a	n/a
Multiple*	Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials. DL Hershman, C Till, JD Wright D Awad, S Ramsey, W Barlow, L Minasian, JM Unger. <u>Journal of Clinical Oncology</u> , Sep 1;34(25):3014-3022, 2016. 2016 Jun 20 [Epub ahead of print]. PMID27325863; PMC5012713 http://www.ncbi.nlm.nih.gov/pubmed/27325863 *studies: S0003, S0007, S0009, S0012, S0022, S0023, S0027, S0028, S0029, S0032, S0102, S0219, S0221, S0329, S0421, S0536, S0819, S9712, S9900, S9902, S9912, S9914, S9916.	n/a	n/a
Multiple	Development and evaluation of an approach to using value of information analyses for real-time prioritization decisions within SWOG, a large cancer clinical trials cooperative group. CS Bennette, DL Veenstra, A Basu, LH Baker, SD Ramsey, JJ Carlson. <u>Medical Decision Making</u> Jul;36(5):641-651, 2016. PMID27012232 http://www.ncbi.nlm.nih.gov/pubmed/27012232	n/a	n/a
None	Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. [Review] AW Smith, NL Seibel, DR Lewis, KH Albritton, DF Blair, CD Blanke, A Bleyer, DR Freyer, AM Geiger, B Hayes-Lattin, JV Tricoli, LI Wagner, BJ Zebrack. <u>Cancer</u> , Apr 1;122(7):988-99, 2016. PMID26849003; PMC n/a http://www.ncbi.nlm.nih.gov/pubmed/26849003	n/a	n/a

None	Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. JV Tricoli, DG Blair, CK Anders, WA Bleyer, LA Boardman, J Khan, S Kummar, B Hayes-Lattin, SP Hunger, M Merchant, NL Seibel, M Thurin, CL Willman. <u>Cancer</u> Apr 1;122(7):1017-1028, 2016. Epub 2016 Feb 5. PMID26849082; PMC4803597 http://www.ncbi.nlm.nih.gov/pubmed/26849082	n/a	n/a
None	Addressing skyrocketing cancer drug prices comes with tradeoffs: pick your poison. SD Ramsey, GH Lyman, R Bangs. <u>JAMA Oncology</u> , Apr 1;2(4):425-426, 2016; 2016 Epub ahead of print]; PMID26868102; PMC n/a [opinion article not peer-reviewed] http://www.ncbi.nlm.nih.gov/pubmed/?term=ramsey+s+poison		

CANCER CARE DELIVERY COMMITTEE Abstracts Published/Presented/Accepted (2016)

Multiple*	Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials. DL Hershman, C Till, JD Wright D Awad, S Ramsey, W Barlow, L Minasian, JM Unger. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation. This abstract has also been hand selected to be included in the Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting. <u>J Clin Oncol</u> 34, 2016 (suppl; abstr 10001). http://abstract.asco.org/176/AbstView_176_162825.html [*studies: S0003, S0007, S0009, S0012, S0022, S0023, S0027, S0028, S0029, S0032, S0102, S0219, S0221, S0329, S0421, S0536, S0819, S9712, S9900, S9902, S9912, S9914, S9916]	n/a	n/a
Multiple*	Integrating traditional Electronic Data Capture (EDC) with new systems. C Cook, T Phillips, M Leblanc. Society for Clinical Trials (May 15-18, 2016, Montreal, Quebec, Canada), poster presentation. [*S1400, S1404]	n/a	n/a
None	Usage of Oregon's Death with Dignity Act (DWDA). CD Blanke, ML LeBlanc, DL Hershman, LM Ellis, FL Meyskens. ASCO Palliative Care in Oncology Symposium (Sept 9-10, 2016, San Francisco, CA), poster. <u>Journal of Clinical Oncology</u> 34, 2016 (suppl 26S; abstr 44). http://abstracts.asco.org/180/AbstView_180_172654.html	n/a	n/a

**SWOG
PUBLICATIONS LIST
CANCER CARE DELIVERY COMMITTEE**
(previously Outcomes & Comparative Effectiveness Committee)
2015

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
CANCER CARE DELIVERY COMMITTEE Published/Accepted (2015)			
S0316	Patient income level and cancer clinical trial participation in a prospective survey study. [Research Letter] JM Unger, JR Gralow, KS Albain, SD Ramsey, DL Hershman. <u>JAMA Oncology</u> , 2015 Oct 15:1-3. Epub ahead of print] PMID26468994; PMCID pending http://www.ncbi.nlm.nih.gov/pubmed/26468994	8/1/04	6/15/08
S1007	Tumor marker usage and medical care costs among older early-stage breast cancer survivors. SD Ramsey, NL Henry, J Gralow, D Mirick, W Barlow, R Etzioni, D Mummy, R Thariani, DL Veenstra. <u>Journal Clinical Oncology</u> 33(2):149-155, 2015. PMID25332254; PMC4279234 http://www.ncbi.nlm.nih.gov/pubmed/25332254	1/15/11	n/a
S9346	Adverse health events following intermittent and continuous androgen deprivation in metastatic prostate cancer patients. DL Hershman, JM Unger, JD Wright, S Ramsey, C Till, CM Tangen, W Barlow, C Blanke, IM Thompson, M Hussain. <u>JAMA Oncology</u> , in press.	n/a	n/a
Multiple	The globalization of cooperative groups. M Valdivieso, BW Corn, JE Dancey, DL Wickerham, LE Horvath, EA Perez, A Urton, WM Cronin, E Field, E Lackey, CD Blanke. <u>Seminars in Oncology</u> Oct;42(5):693-712, 2015. PMID26433551; PMC4592942 http://www.ncbi.nlm.nih.gov/pubmed/26433551	n/a	n/a
None	Progress and infrastructure for improved patient outcomes of the National Cancer Institute Network Groups. CD Blanke, W Curran. <u>Seminars in Oncology</u> , Oct;42(5):679-680, 2015. PMID26433548 http://www.ncbi.nlm.nih.gov/pubmed/26433548	n/a	n/a
None	Involving the patient/advocate in publicly-funded cancer research. J Perlmutter, N Roach, ML Smith. <u>Seminars in Oncology</u> Oct;42(5):681-685, 2015. PMID26433549 http://www.ncbi.nlm.nih.gov/pubmed/26433549	n/a	n/a
None	Social media and oncology: the past, present, and future of electronic communication between physician and patient. MA Lewis, AP Dicker. <u>Seminars in Oncology</u> , Oct;42(5):764-771, 2015. PMID26433557 http://www.ncbi.nlm.nih.gov/pubmed/26433557	n/a	n/a

None	Enhancing adolescent and young adult oncology research within the National Clinical Trials Network: rationale, progress, and strategies. AR Weiss, CR Nichols, DR Freyer. <u>Seminars in Oncology</u> , Oct;42(5):740-747, 2015. PMID26433555; PMC4604069 http://www.ncbi.nlm.nih.gov/pubmed/26433555	n/a	n/a
None	Advances in the community oncology setting from cooperative group trials. JL Wade III, NJ Petrelli, W McCaskill-Stevens. <u>Seminars in Oncology</u> Oct;42(5): 686-692, 2015. PMID26433550 http://www.ncbi.nlm.nih.gov/pubmed/26433550	n/a	n/a
None	Genetic testing and tissue banking for personalized oncology: analytical and institutional factors. G Miles, J Rae, SS Ramalingam, J Pfeifer. <u>Seminars in Oncology</u> Oct;42(5):713-723, 2015. PMID26433552 http://www.ncbi.nlm.nih.gov/pubmed/?term=miles+g+genetic	n/a	n/a
None	The diffusion of docetaxel use in patients presenting with metastatic prostate cancer. J Unger, D Hershman, D Martin, R Etzioni, WE Barlow, M LeBlanc, SR Ramsey. <u>Journal of the National Cancer Institute</u> 2014 Dec 24;107(2). Print 2015 Feb. PMID25540245; PMC4326312 http://www.ncbi.nlm.nih.gov/pubmed/25540245	n/a	n/a

CANCER CARE DELIVERY COMMITTEE Manuscripts Submitted (2015)

S1204	Stepwise development of a cancer care delivery research study to evaluate viral infections in cancer patients: SWOG S1204. JM Unger, DL Hershman, K Arnold, R Loomba, R Chugh, JP Hwang, MA O'Rourke, N Bhadkamkar, LX Wang, AB Siegel, TP Cooley, JL Berenberg, BB Bridges, SD Ramsey. <u>Journal of Comparative Effectiveness Research</u> , under review.	n/a	n/a
None	The scientific impact of positive and negative phase III cancer clinical trials. JM Unger, WE Barlow, SD Ramsey, M LeBlanc, CD Blanke, DL Hershman. <u>JAMA Oncology</u> , under review.		

CANCER CARE DELIVERY COMMITTEE Abstracts Published/Presented/Accepted (2015)

S9346	Long term consequences of intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. DL Hershman, JM Unger, JD Wright, S Ramsey, C Till, CM Tangen, W Barlow, C Blanke, IM Thompson, M Hussain. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <u>J Clin Oncol</u> 33:5 (suppl; abstr 5008), 2015. http://abstracts.asco.org/156/AbstView_156_148320.html	5/15/95	9/1/08
-------	---	---------	--------

None	<p>Creating a national collaborative strategy to enhance trial accrual in NCI's National Clinical Trials Network (NCTN) in the era of precision medicine. A Denicoff, G Schroer, H Massett, R Bangs, J Berlin, M Bischoff, F DeSanto, A Duli, S Hartson-Stine, E Horvath, R Lambersky, M Katz, S Ramalingam, W Williams, N Seibel, W McCaskill-Stevens, M Mooney, J Abrams. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. <i>J Clin Oncol</i> 33:5s (suppl; abstr LBA500), 2015. http://abstracts.asco.org/156/AbstView_156_146144.html</p>	n/a	n/a
Multiple	<p>Value of information analyses for real-time prioritization decisions within a cancer clinical trials cooperative group. C Savage Bennette, SD Ramsey, DL Veenstra, A Basu, JJ Carlson. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral session; <i>J Clin Oncol</i> 33:5s, 2015 (suppl; abstr 6506). http://abstracts.asco.org/156/AbstView_156_150519.html</p>	n/a	n/a

**SWOG
PUBLICATIONS LIST
CANCER CARE DELIVERY COMMITTEE**
(previously Outcomes & Comparative Effectiveness Committee)
2014

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
--------------------	---------------------------------	-------------------------------	----------------------------

CANCER CARE DELIVERY COMMITTEE Published (2014)

S0000	Retention of black and white participants in the Selenium and Vitamin E Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S0000). KB Arnold, J Hermos, K Anderson, L Minasian, CM Tangen, J Probstfield, E Cook. <u>Cancer Epidemiology, Biomarkers and Prevention</u> , 23(12):2895-2905, 2014; Epub 2014 Sep 21. PMID:25242051; PMC4257858 http://www.ncbi.nlm.nih.gov/pubmed/25242051	7/15/01	6/24/04
Multiple*	Comparison of survival outcomes among cancer patients treated in and out of clinical trials. JM Unger, WE Barlow, DP Martin, SD Ramsey, M LeBlanc, R Etzioni, DL Hershman. <u>Journal of the National Cancer Institute</u> 106(3):dju002, 2014. PMID24627276; PMC3982777. *Studies: S0001, S0003, S0012, S0124, S0205, S8624, S8710, S8738, S8795, S8797, S8894, S8949, S9008, S9031, S9035, S9308, S9313, S9333, S0509, S9900. http://www.ncbi.nlm.nih.gov/pubmed/24627276	n/a	n/a
(Pending)	Promoting quality and evidence-based care in early-stage breast cancer follow-up. LN Henry, DF Hayes, SD Ramsey, GN Hortobagyi, WE Barlow, JR Gralow. <u>Journal of the National Cancer Institute</u> 106(4):dju034, 2014; Epub 2014 Mar 13. PMID24627271(commentary not within scope of Public Access Policy) http://www.ncbi.nlm.nih.gov/pubmed/24627271	n/a	n/a

CANCER CARE DELIVERY COMMITTEE Abstracts Published/Presented (2014)

Multiple Groups	NCI pilot intervention program to assist accrual for challenging late phase clinical trials. A Denicoff, HA Massett, E Souhan, L Cave, JJ Welch, N Seibel, RF Little, BS Mann, K DiPiazza, MK Rossmann, S Hartson Stine, R Lambersky, F DeSanto, F Fonzi, D Schrag, RA Abrams, DJ Adelstein, PD Brown, MM Mooney, JS Abrams. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 6617), 2014. http://abstracts.asco.org/144/AbstView_144_132024.html	3/1/12	n/a
Multiple	Association between BMI at treatment initiation and cancer survival across multiple SWOG trials. H Greenlee, J Unger, M Leblanc, D Hershman. American Association for Cancer Research International Conference on Frontiers on Cancer Research Prevention (September 28-October 1, 2014, New Orleans, LA), poster presentation.	n/a	n/a

None/AYA	Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer-results from the National Cancer Data Base (1998-2011). C Jeldres, K Pham, S Daneshmand, C Kollmannsberger, B Hayes-Lattin, E Wolffe, K Odem-Davis, CR Porter, CR Nichols. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 4519), 2014. http://abstracts.asco.org/144/AbstView_144_134968.html	n/a	n/a
----------	---	-----	-----

**SWOG
PUBLICATIONS LIST
OUTCOMES & COMPARATIVE EFFECTIVENESS COMMITTEE
2013**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
OUTCOMES & COMPARATIVE EFFECTIVENESS PUBLISHED (2013)			
S0221	Supplement use of antioxidant during an intergroup clinical trial for breast cancer. G Zirpoli, P Brennan, CC Hong, S McCann, G Ciupak, W Davis, JM Unger, GT Budd, DL Hershman, HCF Moore, J Stewart, C Isaacs, T Hobday, M Salim, G Hortobagyi, J Gralow, K Albain, C Ambrosone. <u>Breast Cancer Research and Treatment</u> , 137(3):903-13, 2013. PMID23306462; PMC3552360 http://www.ncbi.nlm.nih.gov/pubmed/23306462	11/01/03	1/15/12
S1007	Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating OncotypeDx-guided management for women with breast cancer involving lymph nodes. S Ramsey, W Barlow, A Gonzalez-Angulo, S Tunis, L Baker, J Crowley, P Deverka, D Veenstra, G Hortobagyi. <u>Contemporary Clinical Trials</u> 34(1):1-9, 2013. PMID23000081; PMC3525786 http://www.ncbi.nlm.nih.gov/pubmed/23000081	01/15/11	n/a
S1007	Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. R Thariani, NL Henry, SD Ramsey, DK Blough, B Barlow, JR Gralow, DL Veenstra. <u>Journal of Comparative Effectiveness Research</u> 2(3):325-234, 2013. PMID:24236631 http://www.ncbi.nlm.nih.gov/pubmed/24236631	01/15/11	n/a
S1007	Value of information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. JJ Carlson, R Thariani, J Roth, J Gralow, NL Henry, L Esmail, P Deverka, S Ramsey, L Baker, D Veenstra. <u>Medical Decision Making</u> , 33(4):463-471, 2013. PMID2365833 http://www.ncbi.nlm.nih.gov/pubmed/23635833	n/a	n/a
None	Patient income level and cancer clinical trial participation. J Unger, D Hershman, K Albain, C Moinpour, J Petersen, K Burg, J Crowley. <u>Journal of Clinical Oncology</u> 31(5):536-542, 2013 PMID23295802;PMC3565180 http://www.ncbi.nlm.nih.gov/pubmed/23295802	n/a	n/a
Multiple*	Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial. MW Redman, BH Goldman, M LeBlanc, A Schott, L Baker. <u>Clinical Cancer Research</u> , 19(10):2646-2656, 2013. PMID 23669424; (review article – not subject to Public Access Policy). *Studies: S8797, S9008, S9308, S9313, S9321, S9425, S9438, S9509, S0001, S0124. http://www.ncbi.nlm.nih.gov/pubmed/23669424	n/a	n/a

Multiple	Implementation of timeline reforms significantly speeds up initiation of NCI-sponsored trials. JS Abrams, M Mooney, J Zwiebel, G Hortobagyi, S Friedman, S Finnigan, P Schettino, A Denicoff, M Kruhm, M Montello, R Misra, S Ansher, K DiPiazza, E Souhan, L Wickerham, BJ Giantonio, R O'Donnell, DM Sullivan, N Soto, G Fleming, S Prindiville, RA Petryshyn, J Hautala, O Grad, RM Meyer, JC Yao, LH Baker, J Buckner, J Doroshow. <u>Journal of the National Cancer Institute</u> . 105(13):954-959, 2013. PMID23776198; PMC3699438 http://www.ncbi.nlm.nih.gov/pubmed/?term=abrams+js+timeline+reforms	n/a	n/a
----------	---	-----	-----

**SWOG
PUBLICATIONS LIST
OUTCOMES & COMPARATIVE EFFECTIVENESS COMMITTEE
2012**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
OCE MANUSCRIPTS PUBLISHED/PRESENTED (2012)			
S1007	The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). W Wong, SD Ramsey, W Barlow, LP Garrison, DL Veenstra. <u>Contemporary Clinical Trials</u> , 33(6):1117-23, 2012. PMID2298189; PMC3486702 http://www.ncbi.nlm.nih.gov/pubmed/22981891	01/15/11	n/a
S1007	Design of a clinical trial for testing the ability of a continuous marker to predict therapy benefit. Barlow WE. In J Crowley and A Hoering (Editors). Handbook of Statistics in Clinical Oncology, 3 rd Ed. CRC Press, 2012, Ch. 19, p. 293-304. [Book Chapter – PMCID or NIHMSID not applicable] (note: also listed under Breast Committee)	01/15/11	n/a
S1007	Prioritization in comparative effectiveness research: the CANCERGEN experience in cancer genomics. R Thariani, W Wong, JJ Carlson, L Garrison, S Ramsey, PA Deverka, L Esmail, S Rangarao, C Hoban, L Baker, DL Veenstra. <u>Medical Care</u> 50(5):388-393, 2012. PMID22274803; PMC3469160 http://www.ncbi.nlm.nih.gov/pubmed/22274803	n/a	n/a
S1007	Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. P Deverka, D Lavalley, PJ Desai, LC Esmail, SD Ramsey, DL Veenstra, SR Tunis. <u>Journal of Comparative Effectiveness Research</u> 1(2):181-194, 2012. PMID22707880; PMC3371639 http://www.ncbi.nlm.nih.gov/pubmed/22707880	n/a	n/a
Multiple	Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. AT Schroen, GR Petroni, H Wang, MJ Thielen, R Gray, J Benedetti, XF Wang, DJ Sargent, DL Wickerham, W Cronin, B Djulbegovic, CL Slingluff. <u>Clinical Cancer Research</u> 18(1):256-262, 2012. PMID21976533; http://www.ncbi.nlm.nih.gov/pubmed/21976533	n/a	n/a
None	The automatic clinical trial: leveraging the electronic medical record in multisite cancer clinical trials. K Goodman, J Krueger, J Crowley. <u>Current Oncology Reports</u> 14(6):502-508, 2012. PMID22907283; PMC3490046 http://www.ncbi.nlm.nih.gov/pubmed/?term=goodman+k+automatic	n/a	n/a

ABSTRACTS PUBLISHED/PRESENTED (2012)

S0000	Challenges of collecting health data and maintaining contact with an aging study population. J Hartline, K Anderson, D Marrah, E Klein. Society for Clinical Trials 33 rd Annual Meeting (May 20-23, 2012, Miami, FL), oral presentation.	7/15/01	6/24/04
Multiple	Strategies to increase efficiency in protocol development. K Stoermer. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), publication only; 30(suppl; abstr e16508), 2012. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100857	n/a	n/a
Multiple	Provision of coverage analysis in multi-site clinical trials particularly supports smaller, community-based practices K Stoermer, K Willenberg, LH Baker. Society for Clinical Trials 33 rd Annual Meeting (May 21-23, 2012, Miami, FL), (poster presentation); abstr P110, p. 153 (program booklet), 2012. http://www.sctweb.org/public/search/detail.cfm?ID=FB76EAA9-D7E5-9D48-466D22CC361811F3	n/a	n/a
None	Lower income patients less likely to participate in cancer clinical trials. J Unger, D Hershman, K Burg, C Moynour, J Peterson, K Albain, J Crowley. AcademyHealth Annual Research Meeting (June 14-26, 2012, Orlando, FL), oral (podium) presentation. https://academyhealth.org/files/ARM/Podium%20Presentation%20Abstracts%20updated%206-21.pdf	n/a	n/a
None	Patterns of decision-making about cancer clinical trial participation among online cancer treatment community: a collaboration between SWOG and NexCura. J Unger, D Hershman, D Burg, C Moynour, K Albain, J Petersen, JJ Crowley. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation; <u>Journal of Clinical Oncology</u> 30, 2012 (suppl; abstr CRA6009). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97158	n/a	n/a

**SWOG
PUBLICATIONS LIST
OUTCOMES AND COMPARATIVE EFFECTENESS COMMITTEE
2011**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
Outcomes and Comparative Effectiveness Committee Manuscripts Published/Presented/Accepted (2011)			
Multiple	Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. AT Schroen, GR Petroni, H Wang, R Gray, XF Wang, W Cronin, DJ Sargent, J Benedetti, DL Wickerham, B Djulbegovic, CL Slingluff. <u>Clinical Trials</u> 7(4):312-321, 2010. PMID: 20595245 http://www.ncbi.nlm.nih.gov/pubmed?term=Schroen%20at%20preliminary	n/a	n/a
Multiple	Prioritization in comparative effectiveness research: the CANCERGEN experience in cancer genomics. R Thariani, W Wong, JJ Carlson, L Garrison, S Ramsey, PA Deverka, L Esmail, S Rangarao, C Hoban, L Baker, DL Veenstra. <u>Medical Care</u> , accepted 8/11.	n/a	n/a
Outcomes and Comparative Effectiveness Committee Manuscripts Submitted (2011)			
S0221	Effect of physician recommendations on use of antioxidant supplements during an intergroup clinical trial for breast cancer. G Zirpoli, P Brennan, CC hong, S McCann, G Ciupak, W Davis, JM Unger, GT Budd, DL Hershman, HCF Moore, J Stewart, C Isaacs, T Hobday, M Salim, G Hortobagyi, J Gralow, K Albain, C Ambrosone, <u>Journal of the National Cancer Institute</u> , submitted 9/2/11. (also reported under Breast Committee)	11/01/03	n/a
Outcomes and Comparative Effectiveness Committee Abstracts Published/Presented/Accepted (2011)			
*S0000	A secure website for participant submission of follow-up data. JA Hartline, A Smith, K Anderson. Society for Clinical Trials 2011 meeting, oral presentation.	7/25/01	6/24/04
S0000	The consent process for transitioning a large trial to centralized follow-up. M Yee, JA Hartline, K Anderson. American Society of Preventive Oncology Meeting 2011, poster presentation.	7/25/01	6/24/04
S0000	Study transition from local in-person follow-up to centralized follow-up by mail. K Anderson, J Hartline, J Harris-Talley. American Society of Preventive Oncology 2011 Annual Meeting, poster presentation.	7/15/01	6/24/04

S0221	<p>Effect of physician recommendation on multivitamin and antioxidant supplement use during chemotherapy in an adjuvant trial for breast cancer (SWOG S0221). G Zirpoli, PM Brennan, CC Hong, SC McCann, JM Unger, G Budd, D Hershman, J Stewart, C Isaacs, T Hobday, M Salim, G Hortobagyi, J Gralow, K Albain, D Hayes, C Ambrosone. American Association for Cancer Research 2011 Annual Meeting, poster presentation.</p> <p>http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=73b6a59d-cfe5-4b41-b6cc-bbc9f6572757&cKey=59dfd466-c618-420e-9bb8-11ba423d3e89&mKey=%7b507D311A-B6EC-436A-BD67-6D14ED39622C%7d</p>	11/1/03	n/a
S1007	<p>Incorporating comparative effectiveness research study endpoints into the treatment for positive node, endocrine responsive breast cancer (RxPONDER) study. SD Ramsey, WE Barlow, C Moinpour, AM Gonzalez-Angulo, GN Hortobagyi, DL Veenstra, LP Garrison, SR Tunis, LH Baker. ASCO 2011 annual meeting (June 4-8, 2011, Chicago, IL), "Trials in Progress" poster presentation.</p> <p>http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82693</p>	01/15/11	n/a
S1007	<p>SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor (HR)-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less. AM Gonzalez-Angulo, WE Barlow, JR Gralow, F Meric-Bernstam, DF Hayes, CM Moinpour, SD Ramsey, A Schott, D Sparks, KS Albain, GN Hortobagyi. ASCO 2011 meeting, "Trials in Progress" poster presentation. <i>Journal of Clinical Oncology</i> 29: 2011 (suppl; abstr TPS104). (also listed under Breast Committee)</p> <p>http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76547</p>	01/15/11	n/a

**SWOG
PUBLICATIONS LIST
OUTCOMES AND COMPARATIVE EFFECTENESS COMMITTEE
2010**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
Manuscripts Published/Presented (2010)			
S0000	Impact of supplemental site grants to increase African American accrual for SELECT. ED Cook, KB Arnold, JA Hermos, W McCaskill-Stevens, S Moody-Thomas, JL Probstfield, SJ Hamilton, RD Campbell, KB Anderson, LM Minasian. Submitted to <u>Clinical Trials: Journal of the Society for Clinical Trials</u> 7(1):90-99, 2010 PMID: 20156960 http://www.ncbi.nlm.nih.gov/pubmed/		
C49907	Adherence and persistence with oral adjuvant chemotherapy in older women with early –stage breast cancer in CALGB 49907: adherence companion study 60104. A Partridge, L Archer, A Kornblith, J Gralow, D Grenier, E Perez, A Wolff, X Wang, Kastrissios, D Berry, C Hudis, E Winer, H Muss. <u>Journal of Clinical Oncology</u> 28(14): 2418-2422, 2010. PMC2881723; PMID20368559 http://www.ncbi.nlm.nih.gov/pubmed/20368559	7/15/02	12/29/06
None	A national cancer clinical trials system for the 21 st Century: reinvigorating the NCI Cooperative Group JF Scoggins, SD Ramsey. <u>Journal of the National Cancer Institute</u> 102(17):1371, 2010. PMID20682918; PMC2935476 http://www.ncbi.nlm.nih.gov/pubmed/20682918	n/a	n/a
None	Preliminary evaluation of factors associated with pre-mature trial closure and feasibility of accrual benchmarks in phase III oncology trials. AT Schroen, GR Petroni, H Wang, R Gray, XF Wang, W Cronin, DJ Sargent, J Benedetti, DL Wickerham, B Djulbegovic, CL Slingluff. <u>Clinical Trials</u> 7(4):312-321, 2010. (Free full text) PMID20595245 http://www.ncbi.nlm.nih.gov/pubmed?term=Schroen%20at%20benchmarks	n/a	n/a
Abstracts Published/Presented (2010)			
S0000	Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial. E Cook, K Arnold, J Hermos, W McCaskill-Stevens, S Moody-Thomas, J Probstfield,, S Hamilton, R Campbell, K Anderson, L Minasian. Society of Clinical Trials 2010 Annual Meeting, poster presentation. http://ctj.sagepub.com/content/7/4/418.full.pdf+html?rss=1	7/25/01	6/24/04
S0000	Impact of supplemental site grants to increase African American accrual for the selenium and vitamin E cancer prevention trial. E Cook, K Arnold, J Hermos, W McCaskill-Stevens, S Moody-Thomas, J Probstfield,, S Hamilton, R Campbell, K Anderson, L Minasian. NCI/ASCO meeting "Cancer Trial Accrual Symposium: Science and Solutions," Bethesda, MD, April 29-30, 2010, poster presentation.	7/25/01	6/24/04

S0000	Infrastructure for successful recruitment when conducting a multi-site clinical trial: the SELECT experience. KB Anderson, ED Cook, SJ Hamilton, LM Minasian, JA Hermos, JL Probstfield. NCI/ASCO meeting "Cancer Trial Accrual Symposium: Science and Solutions," Bethesda, MD, April 29-30, 2010, poster presentation.	7/25/01	6/24/04
S0000	The role of a community based organization in a large prevention trial. SJ Hamilton, ED Cook, KB Anderson, JQ Sheats. Submitted 2/10 to NCI/ASCO meeting, "Cancer Trial Accrual Symposium: Science and Solutions," Bethesda, MD, April 29-30, 2010, poster presentation.	7/25/01	6/24/04
S0000	Video productions in SELECT: effective tools for staff learning and participant motivation in clinical trials. JM Harris-Talley, D Arney, K Anderson, JA Hartline. Society for Clinical Trials 2010 Meeting (May 16-19, 2010, Baltimore, MD); poster presentation. http://ctj.sagepub.com/content/7/4/418.full.pdf+html?rss=1	7/25/01	6/24/04